Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WholePeople.com

This article was originally published in The Tan Sheet

Executive Summary

Whole Foods Market announces Jan. 14 the formation of WholePeople.com, an e-commerce company offering products such as nutritional supplements, herbals and alternative/holistic health care items. WholePeople has issued $35 mil. in common stock to the venture capital firms Oak Investment Partners, Invesco Private Capital, North Castle Partners and Essex Woodlands Health Ventures in exchange for a 22% minority interest in the company. Whole Foods, which owns the supplement firm Amrion, initially created WholePeople as a subsidiary

You may also be interested in...



WholePeople.com Launch Aims To Revive Struggling Amrion Business

Whole Foods Market remains "optimistic" that the recent sluggish performance of its former Amrion subsidiary can be reversed with new marketing support under the WholePeople.com e-commerce venture.

WholePeople.com Launch Aims To Revive Struggling Amrion Business

Whole Foods Market remains "optimistic" that the recent sluggish performance of its former Amrion subsidiary can be reversed with new marketing support under the WholePeople.com e-commerce venture.

WholePeople.com Launch Aims To Revive Struggling Amrion Business

Whole Foods Market remains "optimistic" that the recent sluggish performance of its former Amrion subsidiary can be reversed with new marketing support under the WholePeople.com e-commerce venture.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel